Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023

Tevogen Bio Holdings Inc.

Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.
Combined company to be named Tevogen Bio Holdings Inc., expected to trade on NYSE American as TVGN/TVGNW.
Transaction approved by both boards; closing subject to SEC review, shareholder approval, and other conditions.
Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies in virology, oncology, neurology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.